A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper, Sara Akhavanfard, Rebecca S Heist, Jennifer Temel, James G Christensen, John C Wain, Thomas J Lynch, Kathy Vernovsky, Eugene J Mark, Michael Lanuti, A John Iafrate, Mari Mino-Kenudson, Jeffrey A Engelman. Sci Transl Med 2011
Times Cited: 2221




List of shared articles



Times cited

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
0

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.
Julia Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Minchom. Crit Rev Oncol Hematol 2021
3

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
2

When the MET receptor kicks in to resist targeted therapies.
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne. Oncogene 2021
0

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R Joseph, Fiona Simpson. Cells 2021
2

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Ryoji Kato, Hidetoshi Hayashi, Kazuko Sakai, Shinichiro Suzuki, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Yoshikane Nonagase, Kaoru Tanaka, Takeshi Yoshida,[...]. Int J Clin Oncol 2021
1

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong. Pharmaceuticals (Basel) 2021
0


Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M Haikala, Ciric To, Jeffrey J Okoro, Kshiti H Dholakia, Jihyun Choi,[...]. Sci Transl Med 2021
0

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
0

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.
Li Liu, Jingjing Qu, Jianfu Heng, Chunhua Zhou, Yi Xiong, Haiyan Yang, Wenjuan Jiang, Liang Zeng, Songlin Zhu, Yongchang Zhang,[...]. Front Oncol 2021
0

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Carlo Genova, Giovanni Rossi, Marco Tagliamento, Erika Rijavec, Federica Biello, Luigi Cerbone, Lodovica Zullo, Francesco Grossi. Expert Rev Respir Med 2020
8

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu,[...]. Clin Cancer Res 2020
17

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
92


Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
26

MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27




Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
3

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.
Marjorie Aubanel, Aurélie Swalduz, Virginie Avrillon, Louis Doublet, Bénédicte Mastroianni, Eve-Marie Neidhardt-Bérard, Maurice Pérol. Clin Lung Cancer 2020
1

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
Ayesha Murtuza, Ajaz Bulbul, John Paul Shen, Parissa Keshavarzian, Brian D Woodward, Fernando J Lopez-Diaz, Scott M Lippman, Hatim Husain. Cancer Res 2019
67